WINDTREE THERAPEUTICS, INC.
Medtech · Public
AEROSURF: a drug-device combination therapy using a capillary aerosol generator to deliver aerosolized synthetic surfactant (lucinactant) to preterm infants with respiratory distress syndrome
- Grants
- $3.6M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $225K
- 1 award · Health and Human S
- #447 of 4531 in medtech
- Patents
- 15
- 3 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · Igf::ot::igf "K4L Surfactant Aerosol To Reduce Influenza Lung Injury" | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · KL4 Surfactant to Mitigate Radiation-Induced Lung Injury | $985,783 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical study of aerosolized KL4 surfactant for neonatal RDS and BPD prevention | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical study of aerosolized KL4 surfactant for neonatal RDS and BPD prevention | $948,310 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical study of aerosolized KL4 surfactant for neonatal RDS and BPD prevention | $695,364 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 444 | Maximum Fidelity Surgical Simulations, Inc. | $228K | $2.2M |
| 445 | ASURAGEN, INC. | $227K | $13M |
| 446 | HealthMyne, Inc. | $225K | $19M |
| 447 | WINDTREE THERAPEUTICS, INC. | $225K | — |
| 448 | DETON CORP | $225K | — |
| 449 | NANOHYBRIDS INC | $225K | — |
| 450 | XILIS INC | $225K | $109M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Istaroxime-containing Intravenous Formulation For The Treatment Of Acute Heart Failure (ahf)granted
- Istaroxime-containing Intravenous Formulation For The Treatment Of Acute Heart Failure (ahf)granted
- Istaroxime-containing Intravenous Formulation For The Treatment Of Acute Heart Failure (ahf)granted
- Solid Forms Of {5-CYCLOPROPYL-2-[2-(3,6-DIFLUORO-PYRIDIN-2-YLAMINO)-PYRIDIN-4-YL]-PYRIDO[3,4-D]PYRIMIDIN-4-YL}-((S)-3,3-DIMETHYL-PIPERIDIN-4-YL)-AMINEapplication
- Istaroxime and Derivatives thereof for Preventing or Reducing the Risk of Acute Myocardial Arrhythmiaapplication
- Istaroxime-containing Intravenous Formulation For The Treatment Of Pre-cardiogenic Shock And Cardiogenic Shockapplication
- Istaroxime-containing Intravenous Formulation For The Treatment Of Pre-cardiogenic Shock And Cardiogenic Shockapplication
- Intravenous Istaroxime For The Treatment Of Acute Heart Failureapplication
- Intravenous Istaroxime For The Treatment Of Acute Heart Failureapplication
- Istaroxime-containing Intravenous Formulation For The Treatment Of Acute Heart Failure (ahf)application
- Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure (AHF)application
- Solid Forms Of {5-CYCLOPROPYL-2-[2-(3,6-DIFLUORO¬PYRIDIN-2-YLAMINO)-PYRIDIN-4-YL]-PYRIDO[3,4-D]PYRIMIDIN-4-YL }-( (S)-3,3-DIMETHYL-PIPERIDIN-4-YL)-AMINEapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.